Resistance of prostate cancer cell lines to COX-2 inhibitor treatment
- 8 July 2005
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 332 (3) , 800-807
- https://doi.org/10.1016/j.bbrc.2005.05.025
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention TrialNew England Journal of Medicine, 2005
- Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma PreventionNew England Journal of Medicine, 2005
- Celecoxib Inhibits Prostate Cancer Growth: Evidence of a Cyclooxygenase-2-Independent MechanismClinical Cancer Research, 2005
- A Population-Based Study of Daily Nonsteroidal Anti-inflammatory Drug Use and Prostate CancerMayo Clinic Proceedings, 2002
- The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous PolyposisNew England Journal of Medicine, 2000
- Host cyclooxygenase-2 modulates carcinoma growthJournal of Clinical Investigation, 2000
- Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2.Journal of Clinical Investigation, 1997
- Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2Cell, 1995
- Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus systemBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1994
- Prostacyclin in Prostatic Cancer: A Better Marker than Bone Scan or Serum Acid Phosphatase?British Journal of Urology, 1982